List of Technivie drug patents

Technivie is owned by Abbvie Inc.

Technivie contains Ombitasvir; Paritaprevir; Ritonavir.

Technivie has a total of 11 drug patents out of which 0 drug patents have expired.

Technivie was authorised for market use on 24 July, 2015.

Technivie is available in tablet;oral dosage forms.

Technivie can be used as treatment of hcv infection using paritaprevir, treatment of hcv infection using ombitasvir.

The generics of Technivie are possible to be released after 13 April, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(1 year, 6 months from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(2 years from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(2 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(8 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Oct, 2031

(8 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in